Skip to main content
Clinical Trials/NCT05722301
NCT05722301
Withdrawn
Phase 3

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

American Hip Institute1 site in 1 countryNovember 1, 2019

Overview

Phase
Phase 3
Intervention
Testosterone Therapy
Conditions
Arthroplasty, Replacement, Hip
Sponsor
American Hip Institute
Locations
1
Primary Endpoint
Harris Hip Score
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

This randomized-controlled trial will study on the effect of testosterone therapy on patients undergoing total hip replacement. Subjects will be male patients > 50 years with testosterone deficiency undergoing total hip replacement due to severe degenerative joint disease. All participants will receive a total hip replacement and will be randomized to either testosterone therapy or placebo. A total of 80 subjects will be recruited randomized into 2 groups of 40 subjects. Testosterone therapy will be administered once to each patient at 2 weeks before surgery. The long-term follow up will be the same as all patients with patient-reported outcomes after total hip replacement, VAS for pain and satisfaction at regular intervals.

Registry
clinicaltrials.gov
Start Date
November 1, 2019
End Date
November 1, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male patients
  • 50 years of age and older
  • Individuals who have degenerative joint disease requiring total hip replacement after failure of conservative measures.

Exclusion Criteria

  • History of prostate cancer less than 5 years ago or those men whom are not considered to be cancer free
  • History of breast cancer less than 5 years ago or those men whom are not considered to be cancer free
  • History of deep vein thrombosis (DVT)
  • Presence of Factor V Leiden (as seen in labs)
  • Presence of Protein S Deficiency (as seen in labs)
  • History of atherosclerotic artery disease - by history having had a diagnosis made of CAD, MI, or stroke
  • Liver disease (as viewed by liver function tests)
  • Testosterone free level greater than 10pg/mL
  • Hematocrit \>51%; PSA \>= 3ng/mL.

Arms & Interventions

Testosterone Therapy

Intervention: Testosterone Therapy

No Testosterone Therapy

Intervention: No Testosterone Therapy

Outcomes

Primary Outcomes

Harris Hip Score

Time Frame: 1 year

patient-reported outcome measure

Forgotten Joint Score

Time Frame: 1 year

patient-reported outcome measure

Secondary Outcomes

  • Visual Analog Scale(1 year)
  • Patient Satisfaction (reported from questionnaire)(1 year)

Study Sites (1)

Loading locations...

Similar Trials